Immunogenicity of Coxsackievirus Group A Type 16 Strains in Mice

doi:10.3969/j.issn.1674-5817.2016.06.001

Abstract

Abstract: Objective To evaluate immunogenicity of Coxsackievirus group A type 16 strains (CA16) in mice and provide experimental data for further research. Methods The female BALB/c and ICR mice ageing 4, 6, 8 weeks were inoculated subcutaneously, intraperitoneally and intramuscularly with two different doses of CA16 live virus. Blood were respectively taken at 7, 21, 28 and 35 days after inoculation and serum neutralizing antibody titer was analyzed by micro-neutralization test in vitro and six cytokines were determined by ELISA. Results Seroconversion rates of the mice inoculated intramuscularly, intraperitoneally and subcutaneously were 83.33%, 40.00% and 0.00% at 28 days after the first inoculation respectively, and antibody geometric mean titers (GMT) were 1∶169, 1∶32 and 0. Seroconversion rates of the mice inoculated intramuscularly, intraperitoneally and subcutaneously were 100% at 7 days after the boost, and GMT were 1∶813 (4.8-fold), 1∶609 (19-fold) and 1∶32; Seroconversion rate was 100%, which was significantly higher than that of 28 and 21 days at the first inoculation. Neutralizing antibody titersand seroconversion rates of the Balb/c were significantly higher than that of ICR, but effect of the age on the neutralizing antibody titers and seroconversion rates was not significant (P>0.05). The dose has significantly effect on the neutralizing antibody titer and seroconversion rates (P<0.05). In high dose group, the neutralizing antibody titer and seroconversion rates was significantly higher than low dose. interleukin(IL)-10 and tumor necrosis factor (TNF)-a have a significant increase at 7 days after the boost, compared to the 7 days after the first inoculation. Conclusion BALB/c and ICR mice can be used as animal models of CA16 live virus immunogenicity evaluation, and the most sensitive models was 4-6 week old BALB/c mice.

Key words: Coxsackievirus group A type 16 strains (CA16), Immunogenicity, Cytokine, Attenuated live vaccine

CLC Number:

R373.2+3Q95-33

MENG Hua-qing, YANG Ting, XIE Tian-hong, LI Hua, YUE Lei, SONG Xia, ZHANG Ye, XIE Zhong-ping. Immunogenicity of Coxsackievirus Group A Type 16 Strains in Mice[J]. Laboratory Animal and Comparative Medicine, 2016, 36(6): 409-414.

References

[1] 陈祥鹏, 檀晓娟, 许文波. 柯萨奇病毒A组16型分子流行病学和疫苗研究进展[J]. 病毒学报, 2014, 30(4):483-488.
[2] Ang LW, Koh BK, Chan KP, et al.Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007[J]. Ann Acad Med Singapore, 2009, 38(2):106-112.
[3] Legay F, Leveque N, Gacouin A, et al.Fatal coxsackievirus A-16 pneumonitis in adult[J]. Emerg Infect Dis, 2007, 13(7):1084-1086.
[4] Xu W, Liu CF, Yan L, et al.Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications[J]. Virol J, 2012,9:8.
[5] 朱俊萍, 徐子刚, 陈辉, 等. 2007年北京地区儿童手足口病病原的初步筛查[J]. 病毒学报, 2009, 1(1):23-28.
[6] 杨芳, 于石成, 张菊英, 等. 2008—2011年我国大陆地区重症手足口病流行特征分析[J]. 疾病监测, 2013, 28(11):888-893.
[7] 郭青, 张春曦, 王晓风, 等. 2008-2009年中国大陆手足口病流行特征分析[J]. 疾病监测, 2011, 26(11):852-856.
[8] Li R, Liu L, Mo Z, et al.An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med, 2014, 370(9):829-837.
[9] 王辉强, 蒋建东, 李玉环. 应用2周龄BALB/c小鼠建立EV71动物模型[J]. 药学学报, 2013, 48(3):343-346.
[10] 刘娟, 李康, 杨静, 等. 肠道病毒71型(EV71)ICR乳鼠动物模型的建立[J]. 军事医学, 2011, 35(11):862-866.
[11] Liu L, Zhao H, Zhang Y, et al.Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection[J]. Virology, 2011, 412(1):91-100.
[12] Zhang Y, Cui W, Liu L, et al.Pathogenesis study of enterovirus 71 infection in rhesus monkeys[J]. Lab Invest, 2011, 91(9):1337-1350.
[13] 杨水芝, 谢天宏, 李华, 等. 柯萨奇病毒A组16型疫苗候选株减毒特性的分析[J]. 中国生物制品学杂志, 2015, 28(5):441-448.
[14] 姜广菊, 李华, 杨婷, 等. 柯萨奇病毒A组16型临床分离株的生物学特性分析[J]. 中国生物制品学杂志, 2014, 27(5):607-611.